laboratory assessment of metabolic disorders
TRANSCRIPT
![Page 1: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/1.jpg)
BYPROF. MOUSTAFA RIZK
PROF. OF CLINICAL PATHOLOGYFACULTY OF MEDICINE, UNIVERSITY OF ALEXANDRIA.
Laboratory Assessment Of Metabolic Disorders
10/12/17 06:03
1
![Page 2: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/2.jpg)
Laboratory assessment of disorders of carbohydrates metabolism
10/12/17 06:03
2
![Page 3: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/3.jpg)
When food is ingested there is a parallel rise in blood
glucose level. This increase in blood glucose is
sensed by the ß-cells in the pancreas and as a result,
insulin is secreted.
10/12/17 06:03
3
![Page 4: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/4.jpg)
FROM HYPER TO HYPOGLYC.
10/12/17 06:03
4
![Page 5: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/5.jpg)
Insulin circulates through the body and signals to
the major insulin sensitive organs: muscle, liver
and fat to increase their glucose intake . Insulin
simultaneously leads to a reduction of glucose
production from the liver and other organs . In this
way the hormone insulin counteracts the rise of
glucose in the blood returning the system to its
equilibrium.10/12/17 06:03
5
![Page 6: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/6.jpg)
10/12/17 06:03
6
![Page 7: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/7.jpg)
DIABETES MELLITUS
DEFINITION
Diabetes mellitus is a group of metabolic disorders
of carbohydrate metabolism in which glucose is
underutilized, producing hyperglycemia.
10/12/17 06:03
7
![Page 8: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/8.jpg)
10/12/17 06:03
8
![Page 9: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/9.jpg)
10/12/17 06:03
9
![Page 10: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/10.jpg)
CLASSIFICATION
1.Type 1 DM: autoimmune.
idiopathic.
2. Type 2 DM.
3. Other specific types (2 ry DM):
Acromegaly.
Cortisone treatment.
down’s syndrome
4. Gestational DM.
5. Impaired glucose tolerance.
6. Impaired fasting glucose.10/12/17 06:03
10
![Page 11: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/11.jpg)
10/12/17 06:03
11
![Page 12: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/12.jpg)
CRTERIA OF DIAGNOSIS
Type 2 DM. Classical symptoms of diabetes and RBG> 200 mg/dL. OR
FBG ≥ 126 mg/dL. OR
2 hour OGTT ≥ 200 mg/dL.
Gestational DM:
By OGTT: two out of four criteria :
FBG ≥ 105 mg/dL
1 hour ≥ 190 mg/dL.
2 hour ≥ 165 mg/dL.
3 hour ≥ 145 mg/dL.
10/12/17 06:03
12
![Page 13: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/13.jpg)
Impaired glucose tolerance: Two criteria
FBG < 126 mg/dL
2 h OGTT 140-199 mg/dL.
Impaired fasting glucose: Two criteria
FBG 111-125 mg/dL
2 h OGTT < 140 mg/dL
10/12/17 06:03
13
![Page 14: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/14.jpg)
ROLE OF THE LAB IN DIABETES MELLITUS
I. Diagnosis: Immunological markers:
-Islet cell antibodies (ICA).
-Insulin auto-antibodies ( IAA).
Genetic markers (e.g., HLA).
Insulin secretion.
Blood glucose.
Oral glucose tolerance curve.
Urine ketones.
Others (e.g., C peptide).
10/12/17 06:03
14
![Page 15: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/15.jpg)
II. Management:
Acute:
Glucose ( blood- urine)
Ketones (blood-urine)
Acid-base status (PH, bicarbonate).
Lactate.
Other abnormalities related to cellular dehydration or
therapy ( K, Na, phosphate, osmolality)
10/12/17 06:03
15
![Page 16: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/16.jpg)
Chronic: Glucose (blood-urine)
Glycated proteins(HbA1C-fructosamine)
Urinary protein
Urinary albumin excretion
Proteinuria
Evaluation of complications( renal function, TG, Cholesterol)
Evaluation of pancreas transplant ( C peptide, insulin)
10/12/17 06:03
16
![Page 17: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/17.jpg)
Laboratory assessment of
disorders of Lipids metabolism
10/12/17 06:03
17
![Page 18: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/18.jpg)
18
Major lipids present in plasma:
Fatty Acids Triglycerides Cholesterol Phospholipids
10/12/17 06:03
![Page 19: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/19.jpg)
19
Triglycerides
Normal level < 160 mg/dl
10/12/17 06:03
![Page 20: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/20.jpg)
20
Triglyceride Structure
10/12/17 06:03
![Page 21: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/21.jpg)
21Cholesterol
Normal level < 200 mg / dl
10/12/17 06:03
![Page 22: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/22.jpg)
22
10/12/17 06:03
![Page 23: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/23.jpg)
23
10/12/17 06:03
![Page 24: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/24.jpg)
24
10/12/17 06:03
![Page 25: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/25.jpg)
25
10/12/17 06:03
![Page 26: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/26.jpg)
26
Classification of Lipoproteins
10/12/17 06:03
![Page 27: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/27.jpg)
27
Lipoprotein metabolism
Exogenous TG Chylomicrons(CM)→ Endogenous TG VLDL→ Exogenous Cholesterol CM→ Endogenous Cholesterol LDL→ Reverse Cholesterol Transport
10/12/17 06:03
![Page 28: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/28.jpg)
28
10/12/17 06:03
![Page 29: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/29.jpg)
29
10/12/17 06:03
![Page 30: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/30.jpg)
30
Selection of patients for investigations
CHD & vascular disease Family history of coronary disease Risk factors for CHD Clinical features of hyperlipideamia Lipeamic plasma
10/12/17 06:03
![Page 31: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/31.jpg)
31
Blood sampling for lipid studies
Serum or plasma 12-14 h fasting for TG,HDL & LDL Fasting or no fasting for total cholesterol Usual diet for 2 weeks Avoid vigorous exercise for 1 day
10/12/17 06:03
![Page 32: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/32.jpg)
Serum Cholesterol 140-200 mg/dL Serum Triglycerides: 50-159 mg/dL. HDL-C 35-80 mg/dL
<35 High risk, > 60 Low risk
LDL-C up to 130 mg/dL < 130 Low risk, >160 High risk
HDL/ Total cholesterol >26% Low risk, < 16 % High risk
LDL/HDL > 5% High risk, < 3 % Low risk
Total lipids up to 550 mg/dL.10/12/17 06:03
32
![Page 33: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/33.jpg)
LIPOPROTEIN ELECTROPHORESIS
During electrophoresis, the lipoproteins separate (in order of decreasing mobility) into 4 fractions : alpha, pre-beta, beta lipoproteins and chylomicrons
10/12/17 06:03
33
![Page 34: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/34.jpg)
VALUE OF LIPOGRAM
Increased band Patterns
Chylomicrons I
Beta and pre-beta IIb
Broad beta III
Pre-beta IV
Pre-beta and chylomicrons V
Fredrickson DS. Circulation 1975; 51: 209-211.
10/12/17 06:03
34
![Page 35: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/35.jpg)
Laboratory assessment of some protein disorders
10/12/17 06:03
35
![Page 36: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/36.jpg)
NORMAL PROTEIN BANDS
10/12/17 06:03
36
![Page 37: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/37.jpg)
NORMAL PROTEIN BANDS
Albumin 50-60 %α1 Glob 3 - 5 %α2 Glob 5 - 8 %β Glob 8 -12 %Gamma 12-22 %
10/12/17 06:03 37
![Page 38: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/38.jpg)
PROTEIN DENSITY VERSUS THE CURVE
10/12/17 06:03
38
![Page 39: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/39.jpg)
INCREASED ALPHA GLOBULINS
10/12/17 06:03
39
![Page 40: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/40.jpg)
Patterns of Serum Protein Electrophoresis
Alb A1 A2 B GammaChronic N,D N,E E N E infalmmatoryrespnceAcute N,D E E N N,DinflammatoryrespnceSubacuteN,D N E N N
10/12/17 06:03
40
![Page 41: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/41.jpg)
POLYCLONAL GAMMOPATHY WITH DECREASED ALBUMIN
10/12/17 06:03
41
![Page 42: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/42.jpg)
INCREASED GAMMA GLOBULINS
10/12/17 06:03
42
![Page 43: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/43.jpg)
Patterns of Serum Protein Electrophoresis
Alb A1 A2 B GammaHepatic D N N,D bridging cirrhosisMonoclo N,E N,D N N M spikegammopathyMonoclo N,E N,D N M spike N,DgammopathyBiclonal N,E N,D N M spike M spigammopathy
10/12/17 06:03
43
![Page 44: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/44.jpg)
ACUTE PHASE REACTANTS:
C-reactive protein (CRP). Antiprotease inhibitors. Ceruloplasmin. α1 –acid glycoprotein. Fibrinogen. Haptoglobin. C3.
10/12/17 06:03
44
![Page 45: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/45.jpg)
Negative acute phase reactants:
Albumin. Transferrin.
10/12/17 06:03
45
![Page 46: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/46.jpg)
Laboratory assessment of Mineral and bone metabolism
10/12/17 06:03
46
![Page 47: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/47.jpg)
Minerals important in our body include Minerals important in our body include ::
1- Calcium1- Calcium
2- Phosphorus2- Phosphorus
3- Magnesium3- Magnesium
10/12/17 06:03
47
![Page 48: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/48.jpg)
10/12/17 06:0348
![Page 49: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/49.jpg)
10/12/17 06:0349
![Page 50: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/50.jpg)
11.Parathyroid Hormone:.Parathyroid Hormone:
(A)(A)Synthesis and Secretion :Synthesis and Secretion : PTH is synthesized and secreted by the four PTH is synthesized and secreted by the four
parathyroid glands located on the thyroid parathyroid glands located on the thyroid capsule.capsule.
The conc. of free calcium in blood or extra-The conc. of free calcium in blood or extra-cellular fluid is the primary regulator of PTH cellular fluid is the primary regulator of PTH synthesis and secretion.synthesis and secretion.
Magnesium and 1,25(OH)2 D has a minor Magnesium and 1,25(OH)2 D has a minor influence.influence.
10/12/17 06:03
50
![Page 51: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/51.jpg)
(B) Biological Action :Biological Action : PTH increases total and free Ca++, decreases
plasma Ph and increases urinary excretion of inorganic Ph.
On bones:- PTH stimulates bone resorption or bone
formation.
10/12/17 06:03
51
![Page 52: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/52.jpg)
3) In the kidney, PTH : Increases Ca++ reabsorption in the D.C.T. Decreases reabsorption of Ph by proximal T. Inhibits Na+ - H+ antiporter activity which
favors a mild hypercholermic metabolic acidosis in hyperparathyroid states.
Induces 25-hydroxyvit.D – 1α hydrolase, increasing the production of 1,25(OH)2 D which stimulates intestinal absorption of both Calcium and Phosphate.
10/12/17 06:03
52
![Page 53: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/53.jpg)
10/12/17 06:0353
![Page 54: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/54.jpg)
10/12/17 06:0354
![Page 55: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/55.jpg)
10/12/17 06:03
55
![Page 56: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/56.jpg)
(C) Clinical Significance :(C) Clinical Significance :
Determination of PTH is useful : In the D.D. of both hypocalcaemia &
hypercalcaemia. For assessing parathyroid function in renal
failure. For evaluating parathyroid function in bone
and mineral disorders.
10/12/17 06:03
56
![Page 57: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/57.jpg)
10/12/17 06:0357
![Page 58: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/58.jpg)
22.Vit. D & its metabolites.Vit. D & its metabolites::
(A)(A) Synthesis :Synthesis : Vit. D is produced endogenously by exposure of
skin to sunlight and is absorbed from food.
It is then metabolized to its main circulatory form, 25-hydroxyvit. D and then to its biologically active form, 1,25(OH)2 D which is the hormone regulating calcium and phosphate metabolism.
10/12/17 06:03
58
![Page 59: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/59.jpg)
Vit. D & its metabolitesVit. D & its metabolites
10/12/17 06:03
59
![Page 60: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/60.jpg)
Vit. D & its metabolitesVit. D & its metabolites
(B) Biological Actions of 1,25(OH)(B) Biological Actions of 1,25(OH)2 2 D :D :
Ca and ph. concentrations in serum are maintained by the actions of 1,25(OH)2 D on :
1.intestine.
2.bone.
3. kidney.
4.parathyroid glands.
10/12/17 06:03
60
![Page 61: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/61.jpg)
Vit. D & its metabolitesVit. D & its metabolites
1) In the Intestine :
1,25(OH)2 D stimulates calcium absorption, by the duodenum & phosphate absorption by the jujenum and ileum.
2) On bone :
1,25(OH)2 D increases bone resorption by stimulating osteaclastic differentiation
10/12/17 06:03
61
![Page 62: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/62.jpg)
Vit. D & its metabolitesVit. D & its metabolites
3)In the Kidney 3)In the Kidney ::
It inhibits its own synthesis and stimulates its metabolism.
4)On parathyroid glands 4)On parathyroid glands ::
It inhibits the synthesis and secretion of PTH.
10/12/17 06:03
62
![Page 63: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/63.jpg)
Vit. D & its metabolitesVit. D & its metabolites
(C) Clinical Significance :(C) Clinical Significance :Knowing the concentration of 25(OH)D (which
is the best indication of vit. D nutritional status )because it is:
1.the main circulatory form 2.varies less from day to day with sun exposure &diet 3.easily measuredis useful in evaluating :a) hypocalcaemiab) vit. D statusc) bone diseased) other disorders of mineral metabolism
10/12/17 06:03
63
![Page 64: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/64.jpg)
10/12/17 06:0364
![Page 65: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/65.jpg)
3.CalcitoninCalcitonin:
(A) Secretion:
Calcitonin is secreted by the parafollicular or C cells which are distributed throughout the thyroid glands.
10/12/17 06:03
65
![Page 66: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/66.jpg)
CalcitoninCalcitonin
(B) Biological Actions : Pharmacological doses of calcitonin decrease
serum calcium and ph. concentrations by inhibiting osteoclastic bone resorption.
Multiple forms of Circulating calcitonin have been reported in patients with medullary thyroid carcinomas which occurs as a part of the syndromes of MEN-2A, MEN-2B and familial MTC.
10/12/17 06:03
66
![Page 67: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/67.jpg)
MARKERS OF BONE METABOLISM
MARKERS OF BONE FORMATION 1-OSTEOCALCIN
2-ALKALINE PHOSPHATASE
3-PROCOLLAGEN PEPTIDES
MARKERS OF BONE RESORPTION
1-COLLAGEN CROSS LINKS
2-TARTARATE RESISTENT ACID P
10/12/17 06:03
67
![Page 68: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/68.jpg)
MARKERS OF BONE METABOLISM
3-URINARY GALACTOSYL HYDROXYLYSIN
4-URINARY HYDROXYPROLINE
10/12/17 06:03
68
![Page 69: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/69.jpg)
BONE METABOLIC DISORDERS
OSTEOPOROSIS OSTEOMALACIA PAGETS DISEASE RENAL OSTEODYSTROPHY
10/12/17 06:03
69
![Page 70: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/70.jpg)
Paget’s disease
Paget’s (pronounced paj-ets) disease affects bones. Throughout a person’s life bone is constantly breaking
down and growing back. With Paget’s disease the normal process of bone growth is changed. The bone breaks down more quickly, and when it grows again it is softer than normal bone.
Soft bones can bend or break more easily. The area affected by Paget’s disease can become shorter because the bone bends.
With Paget’s disease the bone can also grow larger than before.
Paget’s disease can affect any bone, but usually affects the skull, the hip and pelvis bones and bones in the legs and back.
10/12/17 06:03
70
![Page 71: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/71.jpg)
Lab Studies
Biochemical indices reveal elevated alkaline phosphatase levels of bone origin, due to increased osteoblastic activity and bone formation.
In limited Paget disease, the alkaline phosphatase level may be within the reference range. Procollagen I N-terminal peptide (PINP) recently has emerged as a sensitive serum marker for bone formation.
Many patients with elevated alkaline phosphatase levels have been found to have osteocalcin measurements within the reference range.
10/12/17 06:03
71
![Page 72: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/72.jpg)
In Paget disease, urinary hydroxyproline levels are elevated as they reflect increased osteoclastic activity and bone resorption.
10/12/17 06:03
72
![Page 73: Laboratory Assessment Of Metabolic Disorders](https://reader034.vdocuments.us/reader034/viewer/2022051521/5a672e717f8b9a453d8b4d29/html5/thumbnails/73.jpg)
THANK YOU PROF./MOUSTAFA RIZK
10/12/17 06:03
73